Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil.

Milestone began a Phase III study of etripamil in July. The compound is an intranasal calcium channel blocker that can be self-administered by patients from anywhere to end an acute PSVT episode. Milestone CEO Joseph Oliveto told BioCentury via email that the program "is paradigm changing in the sense that [the] goal is to change the treatment setting from the Emergency Department (where IV drugs are standard of care) to the at home setting."...